GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Shiller PE Ratio

Champions Oncology (Champions Oncology) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Champions Oncology Shiller PE Ratio Historical Data

The historical data trend for Champions Oncology's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Shiller PE Ratio Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Champions Oncology's Shiller PE Ratio

For the Biotechnology subindustry, Champions Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Shiller PE Ratio falls into.



Champions Oncology Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Champions Oncology's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, Champions Oncology's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.19/129.4194*129.4194
=-0.190

Current CPI (Jan. 2024) = 129.4194.

Champions Oncology Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -0.408 100.023 -0.528
201407 -0.640 100.520 -0.824
201410 -0.650 100.176 -0.840
201501 -0.610 98.604 -0.801
201504 -0.423 99.824 -0.548
201507 -0.330 100.691 -0.424
201510 -0.290 100.346 -0.374
201601 -0.280 99.957 -0.363
201604 -0.296 100.947 -0.379
201607 -0.260 101.524 -0.331
201610 -0.050 101.988 -0.063
201701 -0.130 102.456 -0.164
201704 -0.221 103.167 -0.277
201707 -0.060 103.278 -0.075
201710 -0.010 104.070 -0.012
201801 -0.010 104.578 -0.012
201804 -0.060 105.708 -0.073
201807 0.040 106.324 0.049
201810 0.020 106.695 0.024
201901 -0.030 106.200 -0.037
201904 -0.020 107.818 -0.024
201907 -0.060 108.250 -0.072
201910 0.020 108.577 0.024
202001 0.030 108.841 0.036
202004 -0.170 108.173 -0.203
202007 0.010 109.318 0.012
202010 0.000 109.861 0.000
202101 0.070 110.364 0.082
202104 -0.040 112.673 -0.046
202107 -0.010 115.183 -0.011
202110 0.020 116.696 0.022
202201 0.050 118.619 0.055
202204 -0.030 121.978 -0.032
202207 -0.020 125.002 -0.021
202210 -0.001 125.734 -0.001
202301 -0.180 126.223 -0.185
202304 -0.190 127.992 -0.192
202307 -0.190 128.974 -0.191
202310 -0.150 129.810 -0.150
202401 -0.190 129.419 -0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Champions Oncology  (NAS:CSBR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Champions Oncology Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093